Wed, 12 Aug 2026
Markets
DJIA 44,210.31 +0.42% S&P 500 6,204.88 +0.31% NASDAQ 20,398.05 -0.18% RUSSELL 2000 2,271.14 +0.55% FTSE 100 8,786.20 -0.09% DAX 24,120.40 +0.26% NIKKEI 225 39,986.30 +1.02% HANG SENG 24,072.30 -0.44% US 10-YR 4.281% -0.03 CRUDE OIL $67.41 +0.68% GOLD $3,342.10 +0.21% BTC $61,845 -1.12% EUR/USD 1.1782 +0.14% DJIA 44,210.31 +0.42% S&P 500 6,204.88 +0.31% NASDAQ 20,398.05 -0.18% RUSSELL 2000 2,271.14 +0.55% FTSE 100 8,786.20 -0.09% DAX 24,120.40 +0.26% NIKKEI 225 39,986.30 +1.02% HANG SENG 24,072.30 -0.44% US 10-YR 4.281% -0.03 CRUDE OIL $67.41 +0.68% GOLD $3,342.10 +0.21% BTC $61,845 -1.12% EUR/USD 1.1782 +0.14%
Of course the ChatGPT dog cancer vaccine spawned a startup

Of course the ChatGPT dog cancer vaccine spawned a startup

Remember that much-hyped story about an Australian tech entrepreneur using ChatGPT, Grok, and other AI tools to craft a personalized cancer vaccine for his dog? Well, surprise: he's launched a startup. That entrepreneur is Paul Conyngham, who says he is launching Gamgee to offer "personalised mRNA c...

Remember that much-hyped story about an Australian tech entrepreneur using ChatGPT, Grok, and other AI tools to craft a personalized cancer vaccine for his dog? Well, surprise: he's launched a startup.

That entrepreneur is Paul Conyngham, who says he is launching Gamgee to offer "personalised mRNA cancer vaccines for dogs." But his ambitions go well beyond dogs - and pets - with Gamgee's website promising the company will harness AI and genetics to develop personalized treatments for a range of diseases and species, including humans.

At the center of Gamgee's origin story is Rosie, Conyngham's Staffordshire bull terrier-Shar Pei mix, who …

Read the full story at The Verge.